Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Show more

One Kendall Square, Cambridge, MA, 02139, United States

Biotechnology

Healthcare

Market Cap

341.4M

52 Wk Range

$1.41 - $7.75

Previous Close

$5.44

Open

$5.76

Volume

563,090

Day Range

$4.78 - $6.00

Enterprise Value

257.4M

Cash

99.21M

Avg Qtr Burn

-10.98M

Insider Ownership

9.65%

Institutional Own.

79.58%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CMP-002 (Antisense Oligonucleotide) Details SYNGAP1-Related Disorders	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CMP-CPS-001 Details Urea Cycle Disorder	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.